Table of Contents Purpose of This PDQ Summary General Information Stage Information Other Considerations for Pregnancy and Breast Cancer
Early Stage Breast Cancer (Stage I and II) Late Stage Breast Cancer (Stage III and IV) Get More Information From NCI Changes to This Summary (03/27/2008) More Information
Purpose of This PDQ Summary
This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about breast cancer treatment and pregnancy. This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board 1.
Information about the following is included in this summary:
- Pathology.
- Diagnosis.
- Cellular classification.
- Staging.
- Treatment options by cancer stage.
This summary is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.
Some of the reference citations in the summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a formal evidence ranking system 2 in developing its level-of-evidence designations. Based on the strength of the available evidence, treatment options are described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for reimbursement determinations.
This summary is available in a patient version 3, written in less technical language, and in Spanish 4. General Information
Breast cancer is the most common cancer in pregnant and postpartum women,
occurring in about 1 in 3,000 pregnant women. The average patient is between 32
to 38 years of age and, with many women choosing to delay childbearing, it is
likely that the incidence of breast cancer during pregnancy will increase.
Breast cancer pathology is similar in age-matched pregnant and nonpregnant
women. Hormone receptor assays are usually negative in pregnant breast cancer
patients, but this may be the result of receptor binding by high serum estrogen
levels associated with the pregnancy. Enzyme immunocytochemical
receptor assays, however, are more sensitive than competitive binding assays. A study
using binding methods indicated similar receptor positivity between pregnant
and nonpregnant women with breast cancer.[1] The study concluded that
increased estrogen levels during pregnancy could result in a higher incidence
of receptor positivity detected with immunohistochemistry than is detected by
radiolabeled ligand binding, which is because of competitive inhibition by high levels of
endogenous estrogen.
The natural tenderness and engorgement of the breasts of pregnant and lactating
women may hinder detection of discrete masses, and therefore, early diagnoses
of breast cancer. Delays in diagnoses are common, with an average reported
delay of 5 to 15 months from the onset of symptoms.[2-5] Because of this
delay, cancers are typically detected at a later stage than in a nonpregnant,
age-matched population.[6] To detect breast cancer, pregnant and lactating
women should practice self-examination and undergo a breast examination as part
of the routine prenatal examination by a doctor. If an abnormality is found,
diagnostic approaches such as ultrasound and mammography may be used. With
proper shielding, mammography poses little risk of radiation exposure to the
fetus.[7] Mammograms should only be used, however, to evaluate dominant masses
and to locate occult carcinomas in the presence of other suspicious physical
findings.[7] Since at least 25% of mammograms in pregnancy may be negative in
the presence of cancer, a biopsy is essential for the diagnosis of any palpable
mass. Diagnosis may be safely accomplished with a fine-needle aspiration, core biopsy, or
excisional biopsy under local anesthesia. To avoid a false-positive diagnosis
as a result of misinterpretation of pregnancy-related changes, the pathologist
should be advised that the patient is pregnant.[8]
Overall survival of pregnant women with breast cancer may be worse than in
nonpregnant women at all stages;[7] however, this may be due primarily to delayed diagnoses.[9]
Termination of pregnancy has not been shown to have any beneficial effect on
breast cancer outcome and is not usually considered as a therapeutic
option.[2,3,5,10,11] Termination of pregnancy, however, may be considered, based on
the age of the fetus, and if maternal treatment options, such as chemotherapy and
radiation therapy, are significantly limited by the continuation of the
pregnancy.
References
-
Elledge RM, Ciocca DR, Langone G, et al.: Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. Cancer 71 (8): 2499-506, 1993.
[PUBMED Abstract]
-
Hoover HC Jr: Breast cancer during pregnancy and lactation. Surg Clin North Am 70 (5): 1151-63, 1990.
[PUBMED Abstract]
-
Gwyn K, Theriault R: Breast cancer during pregnancy. Oncology (Huntingt) 15 (1): 39-46; discussion 46, 49-51, 2001.
[PUBMED Abstract]
-
Moore HC, Foster RS Jr: Breast cancer and pregnancy. Semin Oncol 27 (6): 646-53, 2000.
[PUBMED Abstract]
-
Rugo HS: Management of breast cancer diagnosed during pregnancy. Curr Treat Options Oncol 4 (2): 165-73, 2003.
[PUBMED Abstract]
-
Clark RM, Chua T: Breast cancer and pregnancy: the ultimate challenge. Clin Oncol (R Coll Radiol) 1 (1): 11-8, 1989.
[PUBMED Abstract]
-
Yang WT, Dryden MJ, Gwyn K, et al.: Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy. Radiology 239 (1): 52-60, 2006.
[PUBMED Abstract]
-
Middleton LP, Amin M, Gwyn K, et al.: Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer 98 (5): 1055-60, 2003.
[PUBMED Abstract]
-
Petrek JA, Dukoff R, Rogatko A: Prognosis of pregnancy-associated breast cancer. Cancer 67 (4): 869-72, 1991.
[PUBMED Abstract]
-
Barnavon Y, Wallack MK: Management of the pregnant patient with carcinoma of the breast. Surg Gynecol Obstet 171 (4): 347-52, 1990.
[PUBMED Abstract]
-
Gallenberg MM, Loprinzi CL: Breast cancer and pregnancy. Semin Oncol 16 (5): 369-76, 1989.
[PUBMED Abstract]
Stage Information
Procedures used for determining the stage of breast cancer should be modified for pregnant women to avoid
radiation exposure to the fetus. Nuclear scans cause fetal
radiation exposure.[1] If such scans are essential for evaluation, hydration and
Foley catheter drainage of the bladder can be used to prevent retention of
radioactivity. Timing of the exposure to radiation relative to the gestational
age of the fetus may be more critical than the actual dose of radiation
delivered.[2] Radiation exposure during the first trimester (>0.1 Gy) may lead to
congenital malformations, mental retardation, and increased relative risk of carcinogenesis. Doses greater than 1 Gy
may produce congenital abnormalities. Doses of 0.1 Gy may
result in fewer defects.
Chest x-rays with abdominal shielding are considered
safe, but as with all radiologic procedures, they should be used only when
essential for making treatment decisions.[1,3] A chest x-ray delivers 0.00008 Gy.[4]
For the diagnosis of bone
metastases, a bone scan is preferable to a skeletal series because the bone
scan delivers a smaller amount of radiation and is more sensitive. A bone scan
delivers 0.001 Gy. Evaluation
of the liver can be performed with ultrasound, and brain metastases can be
diagnosed with a magnetic resonance imaging (MRI) scan. Data on magnetic resonance during pregnancy are not yet available, but gadolinium crosses the placenta and is associated with fetal abnormalities in rats.[5]
References
-
Gwyn K, Theriault R: Breast cancer during pregnancy. Oncology (Huntingt) 15 (1): 39-46; discussion 46, 49-51, 2001.
[PUBMED Abstract]
-
Barnavon Y, Wallack MK: Management of the pregnant patient with carcinoma of the breast. Surg Gynecol Obstet 171 (4): 347-52, 1990.
[PUBMED Abstract]
-
Nicklas AH, Baker ME: Imaging strategies in the pregnant cancer patient. Semin Oncol 27 (6): 623-32, 2000.
[PUBMED Abstract]
-
Gallenberg MM, Loprinzi CL: Breast cancer and pregnancy. Semin Oncol 16 (5): 369-76, 1989.
[PUBMED Abstract]
-
Yang WT, Dryden MJ, Gwyn K, et al.: Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy. Radiology 239 (1): 52-60, 2006.
[PUBMED Abstract]
Other Considerations for Pregnancy and Breast Cancer
Lactation
Suppression of lactation does not improve prognosis. If surgery is
planned, however, lactation should be suppressed to decrease the size and vascularity of
the breasts. If chemotherapy is to be given, lactation should also be suppressed because many antineoplastics (specifically cyclophosphamide and methotrexate), when
given systemically, may occur in high levels in breast milk and would
affect the nursing baby. In general, women receiving chemotherapy should not
breastfeed.
Fetal Consequences of Maternal Breast Cancer
No damaging effects on the fetus from maternal breast cancer have been
demonstrated, and there are no reported cases of maternal-fetal transfer of
breast cancer cells.
Consequences of Pregnancy in Patients with a History of Breast Cancer
Pregnancy does not appear to compromise the survival of women with a previous
history of breast cancer, based on limited retrospective data, and no
deleterious effects have been demonstrated in the fetus.[1-9] Some
physicians recommend that patients wait 2 years after diagnoses before
attempting to conceive. This allows early recurrence to become manifest, which
may influence the decision to become a parent. Little is known about pregnancy
after bone marrow transplantation and high-dose chemotherapy with or without
total-body irradiation. In one report of pregnancies after bone marrow
transplantation for hematologic disorders, a 25% incidence of preterm labor and low
birth weight for gestational-age infants was noted.[10]
References
-
Clark RM, Chua T: Breast cancer and pregnancy: the ultimate challenge. Clin Oncol (R Coll Radiol) 1 (1): 11-8, 1989.
[PUBMED Abstract]
-
Harvey JC, Rosen PP, Ashikari R, et al.: The effect of pregnancy on the prognosis of carcinoma of the breast following radical mastectomy. Surg Gynecol Obstet 153 (5): 723-5, 1981.
[PUBMED Abstract]
-
Petrek JA: Pregnancy safety after breast cancer. Cancer 74 (1 Suppl): 528-31, 1994.
[PUBMED Abstract]
-
von Schoultz E, Johansson H, Wilking N, et al.: Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol 13 (2): 430-4, 1995.
[PUBMED Abstract]
-
Kroman N, Mouridsen HT: Prognostic influence of pregnancy before, around, and after diagnosis of breast cancer. Breast 12 (6): 516-21, 2003.
[PUBMED Abstract]
-
Malamos NA, Stathopoulos GP, Keramopoulos A, et al.: Pregnancy and offspring after the appearance of breast cancer. Oncology 53 (6): 471-5, 1996 Nov-Dec.
[PUBMED Abstract]
-
Gelber S, Coates AS, Goldhirsch A, et al.: Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol 19 (6): 1671-5, 2001.
[PUBMED Abstract]
-
Gwyn K, Theriault R: Breast cancer during pregnancy. Oncology (Huntingt) 15 (1): 39-46; discussion 46, 49-51, 2001.
[PUBMED Abstract]
-
Rugo HS: Management of breast cancer diagnosed during pregnancy. Curr Treat Options Oncol 4 (2): 165-73, 2003.
[PUBMED Abstract]
-
Sanders JE, Hawley J, Levy W, et al.: Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 87 (7): 3045-52, 1996.
[PUBMED Abstract]
Early Stage Breast Cancer (Stage I and II)
Surgery is recommended as the primary treatment of breast cancer in pregnant
women. Since radiation in therapeutic doses may expose the fetus to
potentially harmful scatter radiation[1], modified radical mastectomy is the
treatment of choice. Conservative surgery with postpartum radiation therapy
has been used for breast preservation.[2] An analysis has been performed that
helps predict the risk of waiting to have radiation.[3,4]
If adjuvant
chemotherapy is necessary, it should not be given during the first trimester to
avoid the risk of teratogenicity. Chemotherapy given after the first trimester
is generally not associated with a high risk of fetal malformation but may be
associated with premature labor and fetal wastage. If considered necessary,
chemotherapy may be given after the first trimester. Data on the immediate and
long-term effects of chemotherapy on the fetus are limited.[2,4-9]
Studies using adjuvant hormonal therapy alone or in combination with
chemotherapy for breast cancer in pregnant women are also limited. Therefore,
no conclusion has been reached regarding these options.[10] Radiation therapy, if
indicated, should be withheld until after delivery since it may be harmful to
the fetus at any stage of development.[1]
References
-
Kal HB, Struikmans H: Radiotherapy during pregnancy: fact and fiction. Lancet Oncol 6 (5): 328-33, 2005.
[PUBMED Abstract]
-
Gwyn K, Theriault R: Breast cancer during pregnancy. Oncology (Huntingt) 15 (1): 39-46; discussion 46, 49-51, 2001.
[PUBMED Abstract]
-
Nettleton J, Long J, Kuban D, et al.: Breast cancer during pregnancy: quantifying the risk of treatment delay. Obstet Gynecol 87 (3): 414-8, 1996.
[PUBMED Abstract]
-
Kuerer HM, Gwyn K, Ames FC, et al.: Conservative surgery and chemotherapy for breast carcinoma during pregnancy. Surgery 131 (1): 108-10, 2002.
[PUBMED Abstract]
-
Clark RM, Chua T: Breast cancer and pregnancy: the ultimate challenge. Clin Oncol (R Coll Radiol) 1 (1): 11-8, 1989.
[PUBMED Abstract]
-
Giacalone PL, Laffargue F, Bénos P: Chemotherapy for breast carcinoma during pregnancy: A French national survey. Cancer 86 (11): 2266-72, 1999.
[PUBMED Abstract]
-
Rugo HS: Management of breast cancer diagnosed during pregnancy. Curr Treat Options Oncol 4 (2): 165-73, 2003.
[PUBMED Abstract]
-
Cardonick E, Iacobucci A: Use of chemotherapy during human pregnancy. Lancet Oncol 5 (5): 283-91, 2004.
[PUBMED Abstract]
-
Berry DL, Theriault RL, Holmes FA, et al.: Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 17 (3): 855-61, 1999.
[PUBMED Abstract]
-
Isaacs RJ, Hunter W, Clark K: Tamoxifen as systemic treatment of advanced breast cancer during pregnancy--case report and literature review. Gynecol Oncol 80 (3): 405-8, 2001.
[PUBMED Abstract]
Late Stage Breast Cancer (Stage III and IV)
First-trimester radiation therapy should be avoided. Chemotherapy may be given
after the first trimester as discussed in the section on Early Stage Breast Cancer 5. Because the mother may have a
limited life span (most studies show a 5-year survival rate of 10% in pregnant
patients with stages III and IV disease), and there is a risk of fetal damage
with treatment during the first trimester,[1,2] issues regarding continuation of
the pregnancy should be discussed with the patient and her family. Therapeutic
abortion does not improve prognosis.[1-5]
References
-
Hoover HC Jr: Breast cancer during pregnancy and lactation. Surg Clin North Am 70 (5): 1151-63, 1990.
[PUBMED Abstract]
-
Rugo HS: Management of breast cancer diagnosed during pregnancy. Curr Treat Options Oncol 4 (2): 165-73, 2003.
[PUBMED Abstract]
-
Gwyn K, Theriault R: Breast cancer during pregnancy. Oncology (Huntingt) 15 (1): 39-46; discussion 46, 49-51, 2001.
[PUBMED Abstract]
-
Clark RM, Chua T: Breast cancer and pregnancy: the ultimate challenge. Clin Oncol (R Coll Radiol) 1 (1): 11-8, 1989.
[PUBMED Abstract]
-
Barnavon Y, Wallack MK: Management of the pregnant patient with carcinoma of the breast. Surg Gynecol Obstet 171 (4): 347-52, 1990.
[PUBMED Abstract]
Get More Information From NCI
Call 1-800-4-CANCER
For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 9:00 a.m. to 4:30 p.m. Deaf and hard-of-hearing callers with TTY equipment may call 1-800-332-8615. The call is free and a trained Cancer Information Specialist is available to answer your questions.
Chat online
The NCI's LiveHelp® 6 online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 9:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
Write to us
For more information from the NCI, please write to this address:
- NCI Public Inquiries Office
- Suite 3036A
- 6116 Executive Boulevard, MSC8322
- Bethesda, MD 20892-8322
Search the NCI Web site
The NCI Web site 7 provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families. For a quick search, use our “Best Bets” search box in the upper right hand corner of each Web page. The results that are most closely related to your search term will be listed as Best Bets at the top of the list of search results.
There are also many other places to get materials and information about cancer treatment and services. Hospitals in your area may have information about local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.
Find Publications
The NCI has booklets and other materials for patients, health professionals, and the public. These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials. Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities. NCI materials on these and other topics may be ordered online or printed directly from the NCI Publications Locator 8. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237), TTY at 1-800-332-8615. Changes to This Summary (03/27/2008)
The PDQ cancer information summaries are reviewed regularly and updated as
new information becomes available. This section describes the latest
changes made to this summary as of the date above.
Editorial changes were made to this summary. More Information
About PDQ
Additional PDQ Summaries
Important:
This information is intended mainly for use by doctors and other health care professionals. If you have questions about this topic, you can ask your doctor, or call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). |